{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:58:54Z","timestamp":1776405534491,"version":"3.51.2"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Periprocedural stroke represents a clinically important complication of atrial fibrillation ablation, and effective anticoagulation remains essential for risk reduction. However, the use of intravenous thrombolysis in patients with acute ischemic stroke who have recently received novel oral anticoagulants remains controversial under certain clinical circumstances. This report described an uncommon case of radiofrequency ablation-related ischemic stroke treated with intravenous thrombolysis after dabigatran reversal with idarucizumab. In parallel, we conducted a systematic review and meta-analysis to evaluate the safety and outcomes of this treatment strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included analysis of an index case and a systematic review with meta-analysis. We report a 54-year-old patient who developed acute ischemic stroke shortly after radiofrequency catheter ablation for AF and was treated with intravenous thrombolysis after dabigatran reversal with idarucizumab. In parallel, a systematic literature search was conducted to identify observational studies, cohorts, and case series reporting idarucizumab-enabled thrombolysis in dabigatran-treated stroke patients. Data on intracranial hemorrhage (ICH), favorable functional outcome [modified Rankin Scale (mRS) 0\u20132], and mortality were extracted. Pooled estimates were calculated using random-effects meta-analysis of proportions, and comparative analyses with non-anticoagulated thrombolysis populations were performed using pooled risk ratios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Neuroimaging confirmed an acute cerebral infarction in the left thalamus. The patient had been receiving dabigatran and was treated with intravenous idarucizumab followed by intravenous alteplase. Neurological deficits rapidly improved after thrombolysis, and the patient achieved a favorable recovery over 90 days of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Findings from the systematic review and meta-analysis demonstrated low rates of intracranial hemorrhage, low mortality, and favorable functional outcomes comparable to standard thrombolysis populations. This case, together with accumulating evidence from the literature, supports the short-term safety and clinical effectiveness of idarucizumab-enabled intravenous thrombolysis in dabigatran-treated patients with periprocedural acute ischemic stroke. Therefore, early anticoagulant reversal followed by prompt reperfusion therapy may represent a feasible and safe therapeutic strategy in carefully selected patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1801300","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:22:42Z","timestamp":1776403362000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravenous thrombolysis for acute cerebral embolism during atrial fibrillation ablation: a case report and systematic review with meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Bin","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Neurology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Anzhen Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Na","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Anzhen Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-Tong","family":"Niu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Anzhen Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S0140-6736(16)31257-0","article-title":"Stroke prevention in atrial fibrillation","volume":"388","author":"Freedman","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","article-title":"Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"50","author":"Powers","year":"2019","journal-title":"Stroke"},{"key":"B3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.5853\/jos.2018.01788","article-title":"Consensus guides on stroke thrombolysis for anticoagulated patients from Japan: application to other populations","volume":"20","author":"Toyoda","year":"2018","journal-title":"J Stroke"},{"key":"B4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/1747493016669849.","article-title":"Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: expert opinion","volume":"12","author":"Diener","year":"2017","journal-title":"Int J Stroke"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ccl.2015.12.012","article-title":"Atrial fibrillation ablation and stroke","volume":"34","author":"Aagaard","year":"2016","journal-title":"Cardiol Clin"},{"key":"B8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.hrthm.2011.12.016","article-title":"2012 HRS\/EHRA\/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation","volume":"9","author":"Calkins","year":"2012","journal-title":"Heart Rhythm"},{"key":"B9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s11239-015-1223-5","article-title":"Analysis of anticoagulant prescribing in non-valvular atrial fibrillation and development of a clinical tool for guiding anticoagulant selection","volume":"40","author":"Garber","year":"2015","journal-title":"J Thromb Thrombolysis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/CRD.0000000000000088","article-title":"Non-vitamin K antagonist oral anticoagulants and antiplatelet therapy for stroke prevention in patients with atrial fibrillation","volume":"24","author":"Kumar","year":"2016","journal-title":"Cardiol Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40256-016-0162-7","article-title":"Reversing the effect of oral anticoagulant drugs: established and newer options","volume":"16","author":"Ansell","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1161\/CIRCULATIONAHA.115.019628","article-title":"Idarucizumab: the antidote for reversal of dabigatran","volume":"132","author":"Eikelboom","year":"2015","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s13256-017-1404-2.","article-title":"Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report","volume":"11","author":"Agosti","year":"2017","journal-title":"J Med Case Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jns.2016.09.010","article-title":"Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke","volume":"370","author":"Schulz","year":"2016","journal-title":"J Neurol Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.11.029.","article-title":"Intravenous thrombolysis in acute ischemic stroke after idarucizumab reversal of dabigatran effect: analysis of the cases from Taiwan","volume":"28","author":"Fang","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jocn.2018.09.027.","article-title":"Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment","volume":"59","author":"Meyer","year":"2019","journal-title":"J Clin Neurosci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.clinthera.2020.07.006","article-title":"Dabigatran reversal with idarucizumab preceding thrombolysis in an octogenarian patient with chronic kidney disease and acute stroke: a case report","volume":"42","author":"Laxamana","year":"2020","journal-title":"Clin Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4103\/2452-2473.285015.","article-title":"Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window","volume":"20","author":"Vukorepa","year":"2020","journal-title":"Turk J Emerg Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.jemermed.2019.09.040.","article-title":"Idarucizumab for intravenous thrombolysis and endovascular thrombectomy in acute stroke: a case report","volume":"58","author":"Lin","year":"2020","journal-title":"J Emerg Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3390\/medicina58101355.","article-title":"Idarucizumab in dabigatran-treated patients with acute ischemic stroke receiving thrombolytic therapy","volume":"58","author":"Kikule","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s11239-023-02772-3.","article-title":"Standard operating procedure for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke","volume":"55","author":"Frol","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s11239-018-1723-1","article-title":"Assessment of patients post reversal with idarucizumab","volume":"46","author":"Raco","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1161\/strokeaha.107.510768.","article-title":"Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST)","volume":"39","author":"Wahlgren","year":"2008","journal-title":"Stroke"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.05.004.","article-title":"Intravenous thrombolysis in patients with acute ischemic stroke after a reversal of dabigatran anticoagulation with idarucizumab: a real-world clinical experience","volume":"27","author":"\u0160a\u0148\u00e1k","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/acn3.346.","article-title":"Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - a case report","volume":"3","author":"Mutzenbach","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1161\/strokeaha.116.013550.","article-title":"Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab","volume":"47","author":"Berrouschot","year":"2016","journal-title":"Stroke"},{"key":"B28","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ccr3.1446.","article-title":"Systemic thrombolysis and endovascular thrombectomy in severe acute ischemic stroke after dabigatran reversal with idarucizumab","volume":"6","author":"Binet","year":"2018","journal-title":"Clin Case Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"765037","DOI":"10.3389\/fnagi.2021.765037.","article-title":"Intravenous thrombolysis after reversal of dabigatran with idarucizumab in acute ischemic stroke: a case report","volume":"13","author":"Xie","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000447531.","article-title":"Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a case report","volume":"8","author":"Kafke","year":"2016","journal-title":"Case Rep Neurol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/jnn.0000000000000412.","article-title":"Treatment with intravenous alteplase for acute ischemic stroke after reversal of dabigatran with idarucizumab: a case study","volume":"51","author":"Jala","year":"2019","journal-title":"J Neurosci Nurs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fneur.2019.00230.","article-title":"Immediate reversal of dabigatran by idarucizumab prior to laboratory and imaging results in acute stroke","volume":"10","author":"Hieber","year":"2019","journal-title":"Front Neurol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40263-017-0460-x.","article-title":"Idarucizumab in dabigatran-treated patients with acute ischemic stroke receiving alteplase: a systematic review of the available evidence","volume":"31","author":"Pikija","year":"2017","journal-title":"CNS Drugs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e21406","DOI":"10.7759\/cureus.21406.","article-title":"No time to lose: cases of anticoagulant reversal before thrombolysis in acute ischemic stroke patients","volume":"14","author":"Amin","year":"2022","journal-title":"Cureus"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1161\/strokeaha.119.028327.","article-title":"Dabigatran reversal before intravenous tenecteplase in acute ischemic stroke","volume":"51","author":"Beharry","year":"2020","journal-title":"Stroke"},{"key":"B36","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11239-020-02168-7.","article-title":"Revascularization outcomes following acute ischemic stroke in patients taking direct oral anticoagulants: a single hospital cohort study","volume":"51","author":"Frol","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1177\/1747493019895654.","article-title":"Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases","volume":"15","author":"Kermer","year":"2020","journal-title":"Int J Stroke"},{"key":"B38","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.11.019.","article-title":"Intravenous thrombolysis after idarucizumab application in acute stroke patients-a potentially increased sensitivity of thrombi to lysis?","volume":"28","author":"Oblak J","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40263-021-00792-2.","article-title":"Idarucizumab reversal of dabigatran in patients with acute ischemic stroke and intracranial hemorrhage: comparison with non-idarucizumab-treated patients","volume":"35","author":"Frol","year":"2021","journal-title":"CNS Drugs"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.04.032.","article-title":"Intravenous fibrinolysis in ischemic stroke of large vessel after reversing effect of dabigatran with idarucizumab","volume":"26","author":"Alvarez Bravo","year":"2017","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B41","first-page":"15","article-title":"Thrombolysis in acute ischemic stroke after idarucizumab for dabigatran etexilate reversal in elderly: a case report","volume":"10","author":"Baule","year":"2018","journal-title":"J Vasc Interv Neurol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"E1968","DOI":"10.1212\/WNL.0000000000009155","article-title":"Stroke reperfusion therapy following dabigatran reversal with idarucizumab in a national cohort","volume":"94","author":"Barber","year":"2020","journal-title":"Neurology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.5603\/pjnns.96469.","article-title":"Reversing dabigatran effect with idarucizumab to enable intravenous thrombolysis in patients with acute ischaemic stroke - a single centre experience","volume":"57","author":"W\u0142odarczyk","year":"2023","journal-title":"Neurol Neurochir Pol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s13256-016-1050-0.","article-title":"Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report","volume":"10","author":"Gawehn","year":"2016","journal-title":"J Med Case Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s00415-018-9011-8.","article-title":"Paradoxical elevation of plasma dabigatran after reversal with idarucizumab in stroke thrombolysis","volume":"265","author":"Hosoki","year":"2018","journal-title":"J Neurol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.12809\/hkmj166231.","article-title":"Intravenous stroke thrombolysis after reversal of dabigatran effect by idarucizumab: first reported case in Hong Kong","volume":"24","author":"Lo","year":"2018","journal-title":"Hong Kong Med J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e229128","DOI":"10.1136\/bcr-2018-229128.","article-title":"Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab","volume":"12","author":"Loh","year":"2019","journal-title":"BMJ Case Rep"},{"key":"B48","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00415-017-8410-6.","article-title":"Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis","volume":"264","author":"Ng","year":"2017","journal-title":"J Neurol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.05.006.","article-title":"Systemic thrombolysis for ischemic stroke after antagonizing dabigatran with idarucizumab-a case report","volume":"25","author":"Sch\u00e4fer","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B50","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s13256-019-2326-y.","article-title":"Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report","volume":"13","author":"Ohtani","year":"2019","journal-title":"J Med Case Rep"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.02.025.","article-title":"Thrombolytic therapy in severe cardioembolic stroke after reversal of dabigatran with idarucizumab: case report and literature review","volume":"27","author":"Ohya","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/23969873221131635.","article-title":"Thrombolysis after dabigatran reversal: a nation-wide Italian multicentre study, systematic review and meta-analysis","volume":"8","author":"Romoli","year":"2023","journal-title":"Eur Stroke J"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e209862","DOI":"10.1212\/wnl.0000000000209862.","article-title":"Thrombolysis after dabigatran reversal for acute ischemic stroke: a national registry-based study and meta-analysis","volume":"103","author":"Theodorou","year":"2024","journal-title":"Neurology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jns.2018.03.021.","article-title":"Idarucizumab-facilitated intravenous thrombolysis in acute stroke with dabigatran: two cases with hemorrhagic transformation","volume":"388","author":"Tsai","year":"2018","journal-title":"J Neurol Sci"},{"key":"B55","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1136\/jnnp-2017-316449.","article-title":"Intravenous alteplase and endovascular clot retrieval following reversal of dabigatran with idarucizumab","volume":"89","author":"Tse","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B56","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s11239-017-1476-2.","article-title":"Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases","volume":"43","author":"Vosko","year":"2017","journal-title":"J Thromb Thrombolysis"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1801300\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:22:44Z","timestamp":1776403364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1801300\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":56,"alternative-id":["10.3389\/fcvm.2026.1801300"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1801300","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"article-number":"1801300"}}